Clinical evaluation of Phenserine tartrate Extended Controlled Release Tablet (ECRT) formulation in early mild Alzheimer�s disease and mild to moderate traumatic brain injury
Awarded on January 29, 2024. Full description on SAM.gov.
Overview
- Posted
- January 31, 2024
- Notice type
- Award Notice
Notice details
- Last updated
- Dec 4, 2025
- Award date
- Jan 29, 2024
- Award amount (SAM.gov award notice)
- $2.0M
Identifiers
- Solicitation number
- 75N95022R00041
- Notice ID
- 6079864d59e24239817ddaef458d0f66
- Award number (PIID)
- 75N95024D00002
Description
Award Overview
Award Number
75N95024D00002
Award Amount (SAM.gov award notice)
$2.0M
Award Date
Jan 29, 2024
Awardee
Awardee UEI
ZNQ1VJLJQ827
Original Solicitation
Notice ID: 6079864d59e24239817ddaef458d0f66
Posted Date: Jan 31, 2024
Original Response Deadline: Not specified
Task Orders Under This IDV
Top 10 by total obligated
- $1.2MSigned Sep 25, 2026
- $962.5KSigned Jan 21, 2025
- $962.5KSigned Jan 31, 2024
- $123.5KSigned Sep 25, 2026
More From This Vendor
Top 5 most recent
- $123.5KSigned Sep 25, 2026
- $1.2MSigned Sep 25, 2026
- $962.5KSigned Jan 21, 2025
- —Signed Jan 21, 2025
Contacts
Documents
No documents available.
Lifecycle
75N95022R00041- Pre-Solicitation
- Solicitation
- Awarded
This opportunity has been awarded.
- Pre-SolicitationMar 22, 2023
Clinical evaluation of Phenserine tartrate Extended Controlled Release Tablet (ECRT) formulation in early mild Alzheimer’s disease and mild to moderate traumatic brain injury
- 2×SolicitationApr 12, 2023
Clinical evaluation of Phenserine tartrate Extended Controlled Release Tablet (ECRT) formulation in early mild Alzheimer’s disease and mild to moderate traumatic brain injury
- AwardedCurrentJan 31, 2024
Clinical evaluation of Phenserine tartrate Extended Controlled Release Tablet (ECRT) formulation in early mild Alzheimer�s disease and mild to moderate traumatic brain injury
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Additional Details
Solicitation Number
75N95022R00041
Archive Date
Feb 13, 2024
Place of Performance Country
GBR
Office Address
Bethesda, MD, 20892